CENTANNI, Stefano
 Distribuzione geografica
Continente #
NA - Nord America 272
AS - Asia 176
EU - Europa 52
SA - Sud America 38
Continente sconosciuto - Info sul continente non disponibili 18
AF - Africa 2
Totale 558
Nazione #
US - Stati Uniti d'America 264
SG - Singapore 79
CN - Cina 33
IT - Italia 33
BR - Brasile 29
VN - Vietnam 28
IN - India 14
HK - Hong Kong 11
GB - Regno Unito 8
MX - Messico 5
AR - Argentina 4
DE - Germania 4
BD - Bangladesh 3
CA - Canada 3
IQ - Iraq 2
LT - Lituania 2
MA - Marocco 2
PK - Pakistan 2
UY - Uruguay 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
EC - Ecuador 1
FI - Finlandia 1
FR - Francia 1
JP - Giappone 1
NL - Olanda 1
PE - Perù 1
PL - Polonia 1
TH - Thailandia 1
VE - Venezuela 1
Totale 541
Città #
San Jose 79
Ashburn 36
Singapore 29
Council Bluffs 15
Ho Chi Minh City 14
Bengaluru 13
Hefei 13
Santa Clara 13
Phoenix 11
Hong Kong 10
Milan 10
Dallas 8
Beijing 6
Hanoi 6
New York 5
Naples 4
Chicago 3
Lawrence 3
Muggiò 3
Munich 3
Princeton 3
Rome 3
San Francisco 3
Assago 2
Atlanta 2
Brooklyn 2
Campobasso 2
Charlotte 2
Da Nang 2
Des Moines 2
Humble 2
London 2
Los Angeles 2
Maldonado 2
Mexico City 2
Palermo 2
San Nicola Manfredi 2
Seattle 2
Shenzhen 2
São Paulo 2
Alpestre 1
Anápolis 1
Aptos 1
Baghdad 1
Baku 1
Belo Horizonte 1
Boa Vista 1
Boydton 1
Buenos Aires 1
Buffalo 1
Bắc Ninh 1
Cachoeiro de Itapemirim 1
Caracas 1
Carandaí 1
Cincinnati 1
Contagem 1
Corpus Christi 1
Corrientes 1
Cuauhtémoc 1
Curitiba 1
Delhi 1
Detroit 1
Dubai 1
Formosa 1
Fortaleza 1
Guarulhos 1
Harrisburg 1
Hermoso Campo 1
Itanhém 1
Itapevi 1
Itu 1
Içara 1
Laguna 1
Lahore 1
Legnago 1
Levittown 1
Lima 1
Manassas 1
Manaus 1
Mesquite 1
Milledgeville 1
Monte Alto 1
Montreal 1
Nakhon Ratchasima 1
Ninh Bình 1
Norwalk 1
Nova Iguaçu 1
Passo Fundo 1
Philadelphia 1
Phú Nhuận 1
Piraju 1
Port Saint Lucie 1
Portão 1
Preston 1
Quito 1
Rabat 1
Raleigh 1
Reynosa 1
Rhyl 1
Rignano Flaminio 1
Totale 387
Nome #
Durability of benralizumab effectiveness in severe eosinophilic asthma patients with and without chronic rhinosinusitis with nasal polyps: a post hoc analysis from the ANANKE study 48
Benralizumab in Patients With Severe Eosinophilic Asthma With and Without Chronic Rhinosinusitis With Nasal Polyps: An ANANKE Study post-hoc Analysis 47
Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study 47
Profiling severe asthma: Any relevance for age? An analysis from Severe Asthma Network Italy (SANI) cohort 47
Chronic rhinosinusitis with nasal polyps impact in severe asthma patients: Evidences from the Severe Asthma Network Italy (SANI) registry 45
Switching from one biologic to benralizumab in patients with severe eosinophilic asthma: An ANANKE study post hoc analysis 40
Reply to: Kow CS et al. Are severe asthma patients at higher risk of developing severe outcomes from COVID-19? 40
Point-of-Care Lung Sonography: An Audit of 1150 Examinations 39
ChAracterization of ItaliaN severe uncontrolled Asthmatic patieNts Key features when receiving Benralizumab in a real-life setting: the observational rEtrospective ANANKE study 37
Clinical Features and Efficacy of Benralizumab in Patients with Blood Eosinophil Count Between 300 and 450 Cells/mm3: A Post Hoc Analysis from the ANANKE Study 34
Lung Ultrasound B Lines: Etiologies and Evolution with Age 34
Sustained Effectiveness of Benralizumab in Naïve and Biologics-Experienced Severe Eosinophilic Asthma Patients: Results from the ANANKE Study 33
COVID-19 in Severe Asthma Network in Italy (SANI) patients: Clinical features, impact of comorbidities and treatments 32
Fixed airway obstruction and bronchodilator responsiveness phenotypes in severe asthma population from SANI registry 18
Clinical remission in patients with severe eosinophilic asthma treated with benralizumab over 24 months: Post hoc analysis of the ANANKE study 17
Totale 558
Categoria #
all - tutte 5.018
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.018


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20228 0 0 0 0 0 0 2 2 0 1 3 0
2022/202310 6 0 0 1 1 1 0 1 0 0 0 0
2023/202425 5 1 3 0 0 5 1 2 0 3 5 0
2024/202588 16 2 3 1 2 13 14 5 1 2 17 12
2025/2026348 34 32 22 48 44 21 53 18 47 16 9 4
2026/202776 4 17 47 8 0 0 0 0 0 0 0 0
Totale 558